Kincell advances cell therapy process development from early feasibility to commercial-ready manufacturing. Using a risk-based, phase-appropriate approach, we optimize critical unit operations and build fit-for-purpose analytics to define CQAs and control CPPs. As programs scale, we strengthen specifications, comparability, and workflows for consistent, inspection-ready production.
The cell therapy process development journey transforms early scientific innovation into a scalable, commercially viable manufacturing process. Kincell’s expert, experienced scientists design, optimize, and document each critical unit operation, ensuring that the holistic process consistently and reliably delivers the established target product profile (TPP).
Collected via leukapheresis or donor harvest, then assessed for cell count and viability.
Target cells are enriched using magnetic selection or density separation, removing unwanted cell populations, improving starting purity and process consistency.
Cells are activated with cytokines and stimulatory surfaces, priming signaling pathways that enable efficient genetic modification and/or expansion.
When appropriate, genetic modification introduces therapeutic constructs using viral vectors, electroporation, or non-viral approaches.
Expanded cells proliferate in bags, flasks, bioreactors, or automated closed systems, while phenotype and growth kinetics are continuously monitored.
In-process controls track CQAs, including viability, identity markers, transduction efficiency, and potency surrogates, to ensure manufacturing operations meet defined ranges.
Cells are harvested, washed, and concentrated; activation beads are removed, and media are exchanged to prepare for formulation and final processing.
Establishes the final composition through buffer exchange and cryoprotectant addition, optimizing stability for infusion or long-term frozen storage.
Aseptic processing dispenses the drug product into containers appropriate for patient administration, with secure closures and accurate labeling to ensure an accurate chain of identity.
Applies controlled-rate freezing to maintain viability, function, and performance during shipping and storage.
Confirms the cell therapy’s CQAs align with defined specifications and will comply with regulatory expectations.
From the earliest phases of a cell therapy program through commercial supply, our experts guide the development process, reducing risk, improving quality, and accelerating time to market.
Target Product Profiles and risk-based strategies aligned with IND and long-term commercial goals, while applying DoE-driven process optimization and phase-appropriate analytical approaches to strengthen process understanding, improve consistency, and support regulatory readiness as programs advance.
Kincell applies a risk-based, phase-appropriate strategy that preserves early-phase flexibility while building a clear path to late-stage robustness and regulatory readiness. As early as possible, we work to optimize critical unit operations using fit-for-purpose controls and assays that establish feasibility and inform initial CQAs, without locking in processes too early.
As programs move toward pivotal studies and commercialization, we strengthen process control by defining CPP ranges, tightening specifications, and transitioning to workflows that improve consistency and reduce operator-driven variability. In parallel, analytical methods, especially potency, mature from early development through qualification and validation, supported by structured comparability datasets that enable scale-up/out, and inspection-ready manufacturing.
Autologous and allogeneic cell therapies require tailored process development strategies to ensure reproducible, high-quality drug products that meet the program’s needs.
Autologous process development focuses on managing patient-to-patient variability within a one-batch, one-patient model. Strategies emphasize chain-of-identity controls, reduced manual touchpoints, scalable, scale-out platforms, robust in-process analytics, optimized cryopreservation, and automation readiness to improve consistency, turnaround time, and cost of goods.
Allogeneic process development centers on scalable, batch-based manufacturing with strong control of critical process parameters. Strategies include robust cell banking systems, closed bioreactor expansion, genetic modification optimization, process characterization, comparability planning, and automation to ensure reproducibility, regulatory alignment, and commercial-scale efficiency.
Kincell provides process development across the full cell therapy lifecycle, with our Gainesville, FL, USA facility focused on early CMC and clinical supply, and our Research Triangle Park, NC, USA facility emphasizing pivotal and commercial manufacturing. Together, the two facilities provide scalable and redundant GMP capacity, robust analytics, and expansion-ready infrastructure to ensure long-term program continuity and supply reliability.
Kincell Bio develops and delivers tomorrow’s cell therapy cures by integrating comprehensive, end-to-end capabilities across the full product lifecycle, with deep expertise spanning a broad range of autologous and allogeneic cell therapy modalities.
Integrated Services
Application of design-of-experiment (DoE) methodology to the development of cell-based assays for cell therapies can dramatically reduce the time and cost of...
An inside look at how our CMC expertise, advanced process development, and proven manufacturing operations help innovators accelerate their IND, strengthen late-stage...
The Cornerstones of Cell Therapy Excellence, explores analytical, process development, quality, and manufacturing approaches that enable sustainable progress from early development through...
Talk to an expert
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields
